Interview with CEO of Blue Therapeutics, Stefan Bluemmers, MD

Blue Therapeutics is a Boston based drug discovery and development biotech company. Its disruptive R2i platform technology is utilizing the concept of receptor-interactomics. The company has developed an early pipeline of disruptive opportunities, which demonstrate the broad applicability of the technology across many diseases and receptor classes. Its lead drug candidate, BLUE-181 is approaching IND and has successfully provided the proof of concept and the blueprint for the R2i platform. Targeting the novel HM2K receptor, BLUE-181 is on a de-risked path to become a highly differentiated treatment option in the lead indication Irritable Bowel Syndrome as well as in a range of anxiety disorders. The further preclinical stage pipeline comprises programs in infectious diseases (including SARS-CoV2), breast cancer and Parkinson's disease. Blue Therapeutics has been successfully working in an essentially virtual model and has been funded exclusively by public grants of almost $7M to date.